Junshi Biosciences announced the success of the JS001sc-002-III-NSCLC study, meeting its primary endpoints for the treatment of non-squamous non-small-cell lung cancer. China saw 1.06 million new lung cancer cases and 0.73 million deaths in 2022, with NSCLC being the predominant subtype. The study compared a subcutaneous formulation of toripalimab with chemotherapy. JS001sc showed comparable efficacy and safety to toripalimab injection. This breakthrough marks a shift towards more convenient immunotherapy administration for patients. Junshi Biosciences plans to submit a new drug application in the near future for all approved indications of JS001sc.

Read more at GlobeNewswire: Junshi Biosciences Announces Primary Endpoints Met in